Novo Nordisk: Addressing MASH as a liver manifestation of the metabolic disease - EASL SLD Summit 2025
View
Metabolism, Alcohol & Toxicity
5
Novo Nordisk: Addressing MASH as a liver manifestation of the metabolic disease - EASL SLD Summit 2025
View
Metabolism, Alcohol & Toxicity
5
Novo Nordisk: Addressing MASH as a liver manifestation of the metabolic disease - EASL SLD Summit 2025
View
Metabolism, Alcohol & Toxicity
5
Novo Nordisk: Addressing MASH as a liver manifestation of the metabolic disease - EASL SLD Summit 2025
View
Metabolism, Alcohol & Toxicity
5
Novo Nordisk: Addressing MASH as a liver manifestation of the metabolic disease - EASL SLD Summit 2025
View
Metabolism, Alcohol & Toxicity
1
Novo Nordisk: "Walking the clinical care pathway for NASH: learnings from implementation" - EASL Congress 2023
View
Metabolism, Alcohol & Toxicity
1
Novo Nordisk and Echosens: "Clinical challenge: Updates on the non-invasive toolbox for NASH and Fibrosis" - EASL Congress 2023
View
Metabolism, Alcohol & Toxicity
6
AKH: Entering a New Era in Metabolic Dysfunction-Associated Steatohepatitis: Examining the Clinical Implications of Emerging Disease-Specific Therapies - EASL Congress 2024
View
Metabolism, Alcohol & Toxicity
6
AKH: Entering a New Era in Metabolic Dysfunction-Associated Steatohepatitis: Examining the Clinical Implications of Emerging Disease-Specific Therapies - EASL Congress 2024
View
Metabolism, Alcohol & Toxicity
6
AKH: Entering a New Era in Metabolic Dysfunction-Associated Steatohepatitis: Examining the Clinical Implications of Emerging Disease-Specific Therapies - EASL Congress 2024
View
Metabolism, Alcohol & Toxicity
6
AKH: Entering a New Era in Metabolic Dysfunction-Associated Steatohepatitis: Examining the Clinical Implications of Emerging Disease-Specific Therapies - EASL Congress 2024
View
Metabolism, Alcohol & Toxicity
6
AKH: Entering a New Era in Metabolic Dysfunction-Associated Steatohepatitis: Examining the Clinical Implications of Emerging Disease-Specific Therapies - EASL Congress 2024
